Amoéba (ALMIB): Initiation of coverage – Fighting pathogens, respecting nature

EQS-News: / Key word(s): Research Update/Research Update Amoéba (ALMIB): Initiation of coverage – Fighting pathogens, respecting nature 15.03.2023 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement.   London, UK, 15 March 2023   Amoéba (ALMIB): Initiation of coverage – Fighting pathogens, respecting nature During 2022 Amoéba secured regulatory approval in the United States and a recommendation for approval in the European Union for the active substance used in its innovative biological fungicides. It is now looking to raise €45m to fund operations and site expansion over the next three years. €23m of the financing will be for capital expenditure, primarily on a production plant capable initially of manufacturing sufficient active substance annually to treat 100,000 hectares of crops, 200,000 hectares when extended. Management plans to have this operational by early 2025 to support product roll-out, subject to Amoéba receiving regulatory approval for individual fungicides containing the active substance in 2024.   We are not attempting to calculate a valuation at present. The proposed production plant and extension will be capable of manufacturing sufficient active substance annually to treat 200,000 hectares of crops, which we estimate could represent annual revenues of €26m and gross profit of €19.5m at full utilisation. This is a very small share of the global biocontrol agents market, which a report published by P&S Intelligence noted was worth c $4,850m in 2021 and predicts will increase to c $13,600m by 2030 (ie a CAGR of 12.2%), so further production facilities could follow. Click here to view the full report or here to sign up to receive research as it is published.   All reports published by Edison are available to download free of charge from its website www.edisongroup.com About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings. Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney. Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, please contact Edison: Anne Margaret Crow +44 (0)20 3077 5700 industrials@edisongroup.com Learn more at www.edisongroup.com and connect with Edison on: LinkedIn        www.linkedin.com/company/edison-group-/ Twitter           www.twitter.com/Edison_Inv_Res YouTube       www.youtube.com/edisonitv 15.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:
	Germany
EQS News ID:	1582043

End of News	EQS News Service

show this